VERTEX PHARMACEUTICALS INC / MAVRTX
VERTEX PHARMACEUTICALS INC / MA Financial Overview 2021–2025
Updated Jul 10, 2026Vertex Pharmaceuticals absorbed a massive $4.4 billion acquired research and development charge in FY2024, yet rebounded immediately to generate $15.32 in per-share earnings by the close of FY2025. This rapid profitability recovery underscores the sheer cash-generating power of its cystic fibrosis franchise, which bankrolls an aggressive expansion into new therapeutic areas like pain and kidney disease. The central investment thesis is straightforward: Vertex is effectively leveraging its cystic fibrosis dominance to fund a highly diversified, late-stage pipeline without compromising its balance sheet.
The company’s top-line trajectory reflects this execution, as total revenues grew steadily from $7.57 billion in FY2021 to $12.0 billion in FY2025. To support its push into new markets, management elevated research and development expenses to $3.9 billion in FY2025. Despite this heavy pipeline investment and a prior $5.0 billion cash outlay for Alpine Immune Sciences, Vertex ended FY2025 with a formidable liquidity pool of $12.3 billion and initiated a new $4.0 billion share repurchase program. The market rewarded this blend of cash generation and pipeline advancement, valuing the company at a $115.1 billion market cap and pricing the stock at $453.36—equivalent to 29.6x earnings—at the end of FY2025.
Recent Developments (Q4 2025 and Q1 2026)
Vertex maintained its growth trajectory into Q1 2026, with revenues rising 8% year-over-year to $2,986.9 million. Net income surged 59.5% to $1,031.4 million, aided by a 14% decrease in total costs following the absence of a prior $379 million impairment charge. Casgevy product revenues jumped to $42.9 million for the quarter. Vertex completed a rolling Biologics License Application for povetacicept in IgA nephropathy and utilized a priority review voucher to accelerate the approval timeline. Operationally, the board will shrink to ten members following the departure of director Suketu Upadhyay.
Bulls argue that surging net income and expanding sales justify the valuation of 27.7x earnings as of May 5, 2026. Bears warn that heavy pipeline costs, including $961.6 million in Q1 2026 research expenses, could pressure margins if new therapies face approval delays.
What to watch: FDA acceptance and timeline for the povetacicept application; continued commercial ramp of Casgevy.
Rev
$12.00B
FY2025
NI
$3.95B
FY2025
EPS
$15.46
FY2025
OCF
$3.63B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jul 7, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, totaling a significant acquisition. This transaction is expected to close in the third quarter of 2026 and is not subject to a financing condition, providing clarity for investors on deal certainty. The acquisition aims to enhance Vertex's revenue growth and long-term earnings profile, with projections of exceeding $5 billion in annual revenue and becoming accretive to non-GAAP operating income in 2029. The deal terms include customary closing conditions such as stockholder approval from Crinetics and regulatory clearances. Vertex plans to finance the acquisition using a combination of cash on hand and a $4.5 billion unsecured bridge loan facility. This strategic move signals Vertex's intent to expand its market presence and pipeline, particularly in areas where Crinetics has promising assets like PALSONIFY and atumelnant.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (May 13, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on May 13, 2026, detailing the outcomes of its Annual Shareholder Meeting held on the same date. The most significant outcomes include the overwhelming approval of the 2026 Stock and Option Plan, replacing the previous 2013 plan, and the election of all ten nominated directors to the Board. These approvals indicate strong shareholder confidence in the company's leadership and its long-term incentive strategies. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor and approved, on an advisory basis, the 2025 executive compensation program. While a shareholder proposal regarding the right to act by written consent received majority approval, the company's proposed 2026 Stock and Option Plan secured substantially higher levels of support, signaling a clear priority for management's compensation and equity-based incentive frameworks from the investor base.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 4, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on May 4, 2026, to report its financial results for the three months ended March 31, 2026. While the 8-K itself does not contain the specific financial figures, it references a press release (Exhibit 99.1) that details these results. Investors should refer to the attached press release for comprehensive details on revenue, earnings, and other key financial metrics for the first quarter of 2026. The filing also includes standard exhibit information, such as the interactive data file. This filing serves as the primary notification channel for VRTX's quarterly performance. As such, the associated press release is crucial for understanding the company's operational and financial health as of the end of the first quarter. Investors are advised to review the press release for insights into product sales, pipeline progress impacting financial results, and any forward-looking statements or guidance provided by management.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Apr 29, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K reporting a change in its Board of Directors. Suketu Upadhyay, a current director, has informed the Board of his decision not to stand for re-election at the upcoming 2026 annual meeting of shareholders. This decision stems from Mr. Upadhyay's recent appointment as the forthcoming Chief Financial Officer of Incyte Corporation, a role that presents scheduling conflicts with his board responsibilities at Vertex.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Mar 31, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) has announced a significant regulatory milestone with the completion of its rolling Biologics Licensing Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for povetacicept. This investigational therapy is being pursued for the treatment of immunoglobulin A nephropathy (IgAN) in adults, a condition with significant unmet medical need. The company has leveraged a priority review voucher, which is expected to expedite the FDA's review process. Vertex anticipates an accelerated six-month review timeline from the BLA acceptance date, compared to the standard ten months, potentially bringing this therapy to market sooner if approved.
View all 8-K filings →